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Various signaling pathways coordinate energy metabolism and contractile
function in the heart. Myocardial uptake of long-chain fatty acids largely
occurs by facilitated diffusion, involving the membrane-associated protein,
CD36. Glucose uptake, the rate-limiting step in glucose utilization, is medi-
ated predominantly by the glucose transporter protein, GLUT4. Insulin and
contraction-mediated AMPK signaling each are implicated in tightly regulat-
ing these myocardial ‘gate-keepers’ of energy balance, that is, CD36 and
GLUT4. The insulin and AMPK signaling cascades are complex and their
cross-talk is only beginning to be understood. Moreover, transcriptional regu-
lation of the CD36 and GLUT4 is significantly understudied. This review
focuses on recent advances on the role of these signaling pathways and tran-
scription factors involved in the regulation of CD36 and GLUT4.
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The heart has the highest energy requirements of all
organs in the body. To function properly it is depen-
dent on a continuous production of intracellular ATP
and for this requires a constant and plentiful supply of
fuel. Glucose and long-chain fatty acids are the major
metabolic substrates with which the heart sustains
mechanical performance [1,2]. Current research has
initiated a renewed interest in the regulation of cardiac
utilization of these substrates, especially in the context
of cardio-metabolic diseases.
Glucose catabolism in not only cardiac but also in
skeletal muscle begins with the breakdown of glucose,
which encompasses glycolysis and glucose oxidation.
Glycolysis is the initial sequence of reactions involved
in the breakdown of glucose to pyruvate. This process
occurs outside of the mitochondria, and can be carried
out anaerobically. However, the ATP produced
through glycolysis contributes less than 10% of the
overall ATP production in the healthy heart [3]. The
pyruvate generated from glycolysis is further metabo-
lized within the mitochondria to produce the majority
of carbohydrate-derived ATP (glucose oxidation) [4].
Glucose uptake has been established firmly as the rate-
limiting step in glucose utilization by cardiac and mus-
cle cells [1–3]. Both cardiac and skeletal muscles oxi-
dize glucose to produce energy or temporarily store
glucose as glycogen. The principal glucose transporter
protein that mediates myocellular glucose uptake is
GLUT4, which is an isoform of a family of sugar
transporter proteins containing 12-transmembrane
domains (SLC2A4 gene) [5]. The GLUT4 glucose
transporter is thus a major mediator of glucose
removal from the circulation and, in view of the large
total skeletal muscle mass, a key regulator of whole-
body glucose homeostasis.
While glucose oxidation is a critical source of
myocardial ATP, the healthy adult heart obtains
approximately 50–70% of its required ATP from
Abbreviations
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(long-chain) fatty acids [5]. Therefore, mitochondrial
oxidation of lipids provides a major source of ATP for
the heart, and the cellular processes that regulate lipid
uptake and utilization are important contributors to
maintaining proper myocardial energetic status.
Although numerous proteins are coordinately regu-
lated in order to ensure proper fatty acid utilization in
the cardiomyocyte, a key first step in this process is
the entry of fatty acids into the cell [5]. An important
protein involved in the transport of fatty acids into the
cardiomyocyte is the plasma membrane-associated pro-
tein designated as fatty acid translocase (FAT; also
known as CD36). While multiple proteins are involved
in facilitating fatty acid uptake into the heart, CD36
accounts for approximately 70% of the total fatty acid
taken up by cardiomyocytes [6]. As such, myocardial
metabolism of fatty acids may depend upon proper
CD36 function. Consistent with this, changes in CD36
cellular content and/or function have been implicated
in the alteration of myocardial metabolism in the
pathophysiology of certain cardiovascular diseases [6].
Although there appears to be a preferential use of
fatty acids for energy production, the heart has the
ability to rapidly respond to changes in substrate avail-
ability by switching to another substrate for the gener-
ation of ATP so as to continuously secure its energy
demand. This dynamic balance of substrate utilization
was first described by Philip Randle in 1963 [7,8]. In
essence, the Randle cycle explains the metabolic pro-
cess of energy production as one that involves the
competition of glucose and fatty acids [8]. In addition,
substrate selection occurs based on the availability of
the substrate as well as the energy demand in tissues.
Since the heart requires a steady supply of energy, the
ability of the cardiomyocyte to rapidly switch to differ-
ent substrates based on their availability is a necessary
component of a healthy heart [9]. Evidence is accumu-
lating that the substrate transporters, GLUT4 and
CD36, also serve a role in this dynamic balance of
substrate utilization.
This article reviews the known molecular and cellu-
lar regulatory mechanisms for the substrate trans-
porters GLUT4 and CD36 with a focus on heart and
skeletal muscle, their integration with insulin signaling
and contraction, and the profound effects that GLUT4
and CD36 exert on whole-body substrate metabolism.
Signaling pathways regulating GLUT4
trafficking
GLUT4 is one of 13 sugar transporter proteins
(GLUT1–GLUT12, and H+/myo-inositol transporter)
encoded in the human genome [10,11] that catalyzes
hexose transport across cell membranes through an
ATP-independent, facilitative diffusion mechanism
[12]. The heart expresses mainly GLUT1 and GLUT4,
with GLUT4 expression being approximately four
times higher than that of GLUT1. GLUT1 is constitu-
tively expressed at the sarcolemma and is involved in
basal glucose uptake, whereas GLUT4 displays the
unique characteristic of a mostly intracellular disposi-
tion in the unstimulated state that is acutely redis-
tributed to the plasma membrane in response to
insulin, contraction, and other stimuli [13,14].
Insulin and contraction are the two key stimuli that
acutely regulate GLUT4 recruitment to the cell sur-
faces of heart, skeletal muscle, and adipose cells inde-
pendent of transcription or translation [15,16].
Nevertheless, these physiological stimuli initiate dis-
tinct signaling mechanisms but both lead to enhanced
GLUT4 translocation and glucose uptake. The insulin
signaling pathway to GLUT4 has been discussed in
detail in recent reviews [13,17,18]. Detailed in vivo
studies using genetically engineered mouse models [19]
and, more recently, by siRNA knockdown experiments
in cultured cells [20,21] have demonstrated that the
canonical insulin signaling pathway is triggered by
activation of the IR tyrosine kinase leading to tyrosine
phosphorylation of IR substrate (IRS) proteins and
their recruitment of PI 3-kinase. The latter kinase cat-
alyzes conversion of phosphatidylinositol (4,5)P2 to
phosphatidylinositol (3,4,5)P3 (denoted PIP3). PIP3, in
turn, triggers the activation of the protein kinase Akt
through the actions of two intermediate protein
kinases, PDK1 and Rictor/mTOR [22,23]. Interest-
ingly, Akt2 rather than the Akt1 or Akt3 isoforms
appears to control GLUT4 trafficking in adipose and
muscle cells as well as mediate insulin signaling to con-
trol glucose output in liver [24,25]. Substrates of Akt2
that may mediate the insulin effects on the machinery
of GLUT4 trafficking are being actively investigated.
The GTPase-activating protein TBC1D4, denoted
AS160, is such a substrate [26]. AS160 catalyzes inacti-
vation of critical organizers of intracellular membrane
trafficking, Rab proteins 2A, 8A, 10, and 14 in vitro
[27]. Expression of mutant AS160 lacking Akt-specific
phosphorylation sites inhibits insulin-stimulated
GLUT4 translocation [28], suggesting that it is a nega-
tive regulator that is itself inhibited by insulin through
Akt. AS160 plays a role in insulin-stimulated GLUT4
exocytosis but not in the inhibition by insulin of
GLUT4 endocytosis [29]. However, AS160 knockdown
only partially releases the pool of intracellular GLUT4
mobilized by insulin, and careful analysis suggests that
other unknown Akt substrate proteins must make
major contributions to overall GLUT4 regulation by
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insulin [30,31]. In this context, recent studies have
identified TUG (tether containing a UBX domain for
GLUT4) protein, encoded by the Aspscr1 gene, to
coordinate with signals through Akt2 to AS160/
TBC1D4 and TBC1D1 [32]. The proposed model sug-
gests that TUG traps GLUT4 in intracellular, insulin-
responsive vesicles termed GLUT4 storage vesicles
(GSVs). Insulin triggers TUG cleavage to release the
GSVs; GLUT4 then recycles through endosomes dur-
ing ongoing insulin exposure. The TUG C-terminus
binds a GSV-anchoring site comprising Golgin-160
and possibly other proteins [32]. Adding to the com-
plexity, Sirtuin 2 (SIRT2), a NAD+-dependent
deacetylase, binds TUG and de-acetylates the TUG
peptide. SIRT2 overexpression reduced TUG acetyla-
tion and redistributed GLUT4 and IRAP to the
plasma membrane in 3T3-L1 adipocytes [32] (Fig. 1).
Contraction-induced AS160 phosphorylation is
mediated through the AMP-activated protein kinase
(AMPK) pathway, providing a potential convergence
among insulin, contraction and exercise-mediated
signaling to GLUT4 [33,34]. On the other hand, simul-
taneously disrupting AMPK and Akt failed to com-
pletely inhibit contraction-induced AS160
phosphorylation, which observation is consistent with
the existence of additional signals leading to GLUT4
translocation. Two cellular consequences of contrac-
tion, a transient increase in intracellular calcium con-
centration ([Ca2+]i) and an increase in [AMP]/[ATP]
ratio, are thought to contribute to enhanced GLUT4
translocation to the cell surface [33,34]. The former
signal is mediated through activations of the protein
kinase CaMKII and perhaps conventional protein
kinase C [16,33]. However, the role of AMPK in con-
traction-induced glucose uptake has been questioned.
Muscle-specific overexpression of a dominant-inhibi-
tory catalytic subunit of AMPK (i.e., a2-AMPK, the
major catalytic isoform in skeletal muscle) reduced
contraction-mediated glucose uptake by only 30–40%
[35]. Nevertheless, as has been reported previously,
enhanced muscle glucose uptake in response to activa-








































Fig. 1. Convergence of signaling pathways initiated by insulin and contraction leading to GLUT4 regulation. Insulin signaling through the
PI3K pathway and muscle contraction through elevated AMP/ATP ratios, elevated ROS, and intracellular [Ca2+] levels lead to activation of
downstream protein kinases (AKT, AMPK, PKD) that phosphorylate putative effectors that modulate steps in the GLUT4 trafficking
pathways. AS160 is one such substrate that appears to negatively regulate an early step in GLUT4 exocytosis, via inhibition of RAB
GTPases. Additionally, acetylated TUG has been identified as a novel interacting partner and negative regulator of GLUT4 translocation.
Insulin dissociates TUG from GLUT4, whereas SirT1 deacetylates TUG, both actions ultimately facilitating GLUT4 translocation. At the gene
expression level, several transcription factors have been reported to regulate GLUT4 promoter activity. Dashed lines imply pathways yet to
be experimentally delineated. See text for further details.
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additive to that achieved through muscle contraction,
indicating that AMPK is a component of the contrac-
tion signaling mechanism [36]. Thus, existing evidence
indicates that an AMPK-mediated pathway may be
one of several redundant contraction-induced signaling
mechanisms leading to GLUT4 translocation to the
cell surface. In addition to AMP, other second messen-
gers become elevated during contraction, such as intra-
cellular ROS, Ca2+, and diacylglycerol (DAG) [37].
Both latter second messengers are known activators of
members of the conventional and novel protein kinase
C (PKC) subfamilies, as well as the closely related
PKD family, with its founding member PKD1. More-
over, the classical PKC activators phorbol esters (cell-
permeable DAG analogs) additionally activate PKD1.
Several lines of evidence suggest a crucial role for
PKD1 in contraction-induced glucose uptake. Pharma-
cological PKC inhibitors (which also inhibit PKD1)
and RNAi-mediated silencing of PKD1 each com-
pletely abolish contraction-induced GLUT4 transloca-
tion and glucose uptake in cardiomyocytes [38,39].
Similarly, in cardiomyocytes from cardio-specific
PKD1-KO mice, contraction-induced glucose uptake
was entirely lost [38]. Furthermore, adenoviral overex-
pression of PKD1 in cultured cardiomyocytes [40] and
transgenic mice overexpressing constitutively active
cardiac PKD1 [41] each were shown to elevate both
basal and contraction-induced glucose uptake. Sub-
stantial evidence also indicates that atypical PKC-k/f
acts downstream of PI 3-kinase to relay insulin and
contraction signals to GLUT4 translocation [42,43].
However, there are conflicting results using RNAi
regarding the importance of PKC-k/f on insulin-stimu-
lated glucose uptake in adipocytes [19,41]. Thus, the
precise roles of atypical PKC-k/f in GLUT4 regulation
need further clarification, perhaps from tissue-specific
knockout mice [44].
Endogenous regulation of GLUT4
expression
The profound effects on whole-body glucose home-
ostasis observed in mouse models of GLUT4 defi-
ciency or overexpression heighten the potential
physiological importance of changes in endogenous
GLUT4 expression in different states. For these rea-
sons the mechanisms that regulate GLUT4 expression
are important to clarify, and there is much fertile terri-
tory for exploration in this field. Tissue-specific expres-
sion of GLUT4 in adipose tissue, skeletal muscle, and
cardiac muscle, as well as its regulation by fasting and
refeeding, is conferred within a 2.4-kb DNA segment
at the 50 region of the GLUT4 gene [45]. For skeletal
muscle-specific expression, a region between 522 and
+420 bp has been inferred in transgenic mice to be
important [46]. This region contains an apparent myo-
cyte enhancer factor (MEF)2-binding domain at 466
to 457 bp that is critical for specifying tissue expres-
sion [47] and increased GLUT4 expression during
muscle regeneration [48]. Near this same region it has
been proposed that thyroid hormone receptor and
myoD form a complex with MEF2 to regulate GLUT4
expression [49]. Another domain that has been impli-
cated in the tissue-specific expression of GLUT4 is ter-
med Domain I and includes the region 742 to
712 bp relative to the initiation site for transcription
[50]. Moreover, a factor termed GEF appears to oper-
ate in this region in association with MEF2A [51].
Additionally, it has been reported that the synthetic
thiazolidinedione ligands of peroxisome proliferator-
activated receptor (PPAR)c improve insulin sensitivity
in type 2 diabetes and induce GLUT4 mRNA expres-
sion in adipose tissue and muscle. In primary rat adi-
pocytes and CHO-K1 cells, PPARc1 and PPARc2
repressed GLUT4 promoter activity, whereas this
repression was completely alleviated by rosiglitazone
[52]. The –66 to +163 bp GLUT4 promoter region was
sufficient to mediate PPARc inhibitory effects [52]. In
conjunction to this finding, a recent study has reported
that zinc finger protein (ZFP) 407 regulates insulin-sti-
mulated glucose uptake in adipocytes [53]. ZFP407
deficiency was attributed to a reduction in GLUT4
mRNA and protein levels. The decrease in GLUT4
was due to both decreased transcription of Glut4
mRNA and decreased efficiency of Glut4 pre-mRNA
splicing. Interestingly, ZFP407 coordinately regulated
this decrease in transcription with an increase in the
stability of Glut4 mRNA, resulting in opposing effects
on steady-state Glut4 mRNA levels [53]. Additionally,
cytochrome P450 isoform 2E1 (CYP2E1) has also been
identified as a novel negative regulator of GLUT4
gene expression in insulin-sensitive cells [54]. This inhi-
bitor effect of CYP2E1 on GLUT4 gene expression
was shown to be mediated by the binding of transcrip-
tion factor NF-E2-related factor 2 (NRF2) to the dis-
tal promoter region of GLUT4 [54]. These and other
data suggest a complex mode of GLUT4 regulation at
the transcriptional level that is incompletely under-
stood at present and warrants extensive research.
Signaling pathways regulating CD36
trafficking
CD36 is a multifunctional immuno-metabolic receptor
with various ligands. One of its physiological functions
in the heart is facilitating the high-affinity uptake of
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fatty acids from albumin and from triacylglycerol-rich
lipoproteins. The protein is expressed in endothelial
cells and cardiomyocytes and at both sites is likely to
contribute to fatty acid uptake by the myocardium.
CD36 also transduces intracellular signaling events
that influence how the fatty acid is utilized and that
mediate metabolic effects of fatty acid in the heart
[55]. CD36 was identified as a cellular fatty acid ‘trans-
porter’ (for convenience this term is used although it
was later found that CD36 does not act as a true
membrane transporter for fatty acids but rather facili-
tates the uptake process) in 1993 based on work with
isolated adipocytes [56]. Physiological relevance of this
function of CD36, especially as related to heart meta-
bolism, has been extensively reviewed [2,55]. CD36
was shown to traffic between the cell surface and intra-
cellular compartments (specifically endosomes) and is
recruited to the sarcolemma by either insulin and/or
AMPK in a vesicle-mediated process [57,58] that is
controlled by the Rab GTPase-activating protein
AS160 and its target GTPase, Rab8a [58].
In humans, CD36 is composed of 472 amino acids
that make up a hairpin-like structure with a large
extracellular loop on the extracellular surface of the
plasma membrane. The extracellular domain of the
transmembrane protein is heavily glycosylated result-
ing in an increase in the apparent mass from 53 kDa
(estimated) to 88 kDa (observed) [58]. The protein also
has two phosphorylation sites, three external disulfide
bridges, and contains four palmitoylation sites, two
each at the extreme NH2 and COOH termini [58].
Finally, the COOH terminal domain of CD36 contains
two ubiquitination sites, indicating that CD36 is a
potential target for various signaling modulators in the
context of metabolic homeostasis. Currently, two
major signaling pathways, insulin-mediated signaling
and contraction stimuli, for CD36 trafficking have
been explored in detail. Each relies on specific signal-
ing cascades, which are tightly regulated by an intri-
cate network of kinases (Fig. 2).
In addition to the major role of insulin signaling in
controlling GLUT4 translocation, a number of kinases
in this pathway are involved also in the regulation and
intracellular translocation of CD36 [59]. Interestingly,
and in contrast to the Randle cycle phenomenon,


































Fig. 2. Convergence of signaling pathways initiated by insulin and contraction leading to CD36 regulation. Insulin signaling through the PI3K
pathway and muscle contraction through elevated AMP/ATP ratios lead to activation of downstream protein kinases (AKT, AMPK) that
phosphorylate putative effectors that modulate steps in the CD36 trafficking pathways. AS160 is one such substrate that appears to
negatively regulate an early step in CD36 exocytosis, via inhibition of RAB GTPases. At the gene expression level, several transcription
factors have been reported to regulate CD36 promoter activity. See text for further details.
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acid oxidation, insulin signaling is responsible for the
translocation of both GLUT4 and CD36 to the
sarcolemma [59]. For example, phosphatidylinositol-3-
kinase (PI3K), a key component of the insulin
signaling pathway, is thought to be a key player in
CD36 translocation as PI3K-specific inhibitors, such
as wortmannin and LY-294002, have been shown to
negate these insulin-mediated changes in lipid metabo-
lism [60]. Additionally, PI-2, 4, 5-triphosphate (PIP3),
a product of PI3K, is involved in the activation of
Akt2 [61], while PKC-k/f [62] plays a role in CD36
translocation as well. Furthermore, the PI3K–Akt sig-
naling pathway is also involved in the phosphorylation
of the transcription factor forkhead box O (FoxO),
which results in its nuclear export and inactivation
(Fig. 2). The transcriptional activity of FoxO has been
implicated in promoters of metabolic genes, which
includes CD36 [63]. Thus, insulin signaling has an
added effect of increasing CD36 expression in addition
to increasing CD36 availability at the sarcolemma [63].
Notably, FoxOs can also be inhibited by the deacety-
lase SirT1. Thus, the role of Sirtuins, in general, and
SirT1, in particular, can be of potential interest in the
context of CD36 gene regulation.
Taken together, insulin is involved in not only the
translocation of both GLUT4 and CD36 but also in
upregulating their expression [59]. In the context of
our understanding of the Randle cycle, how or why
insulin simultaneously promotes the potential for both
fatty acid entry and glucose entry has still not been
addressed. In this regard, experiments designed to
titrate the insulin concentration and subsequently
determine the time responsiveness of GLUT4 and of
CD36 translocation are of potential interest. On the
other hand, the observations illustrate that the heart is
an omnivorous organ in that it readily extracts all
available substrates for storage purposes (Fig. 2).
Namely, both glucose and fatty acids will be directed
by further insulin actions (e.g., insulin-mediated
dephosphorylation of glycogen synthase and phospho-
rylation of GPAT, respectively) toward synthetic path-
ways (to produce glycogen and lipid droplets,
respectively).
Just as insulin, contraction simultaneously stimulates
the translocation of GLUT4 and CD36. Contraction-
induced CD36 translocation, similarly to that of
GLUT4, is AMPK dependent [64]. Furthermore, simi-
lar to the PI3K–Akt signaling pathway, FoxO is
downstream of the AMPK pathway, and thus may
lead to enhanced CD36 availability for translocation
to the membrane [65]. Although AMPK activation
induces sarcolemmal recruitment of CD36 [64], on the
flip side CD36 has also been recently reported to
regulate AMPK activation [66]. CD36 was shown to
be important for coordinating the dynamic protein
interactions within a molecular complex consisting of
the CD36 partner tyrosine kinase Fyn, the AMPK
kinase LKB1, and AMPK. CD36 expression maintains
AMPK quiescent by allowing Fyn to access and phos-
phorylate LKB1, promoting its nuclear sequestration
away from AMPK [66]. Palmitate binding to CD36
within minutes activates AMPK via its ability to disso-
ciate Fyn from the complex as CD36 is internalized
into LKB1-rich vesicles. Thus, while CD36 keeps
AMPK inhibited, palmitate binding acts to reverse this
inhibition by activating AMPK [66]. This feedback sig-
naling loop would serve to adjust the capacity for fatty
acid oxidation to match fatty acid availability, and
would explain earlier observations made in cardiomy-
ocytes, where both sarcolemmal CD36 recruitment and
AMPK activation were found to be important for
fatty acid oxidation [67,68]. As a result, contraction-
mediated signaling and CD36 translocation to the
plasma membrane may provide an important mecha-
nism for the heart to increase fatty acid supply in
response to long-term changes in metabolic demand.
Endogenous regulation of CD36
expression
In humans, earlier work has shown that approximately
40% of patients with hypertrophic cardiomyopathy
had decreased or abnormal CD36 expression associ-
ated with impaired myocardial fatty acid uptake [55].
Animal models of altered CD36 expression have
shown detrimental cardiovascular outcomes related to
both decreased and increased CD36 expression [exten-
sively reviewed in 6,55]. Some studies have suggested
cardiac abnormalities in mice lacking CD36 [69,70],
suggesting that the loss of CD36 is detrimental to the
heart. In contrast to the loss of CD36 activity, abnor-
mal accumulation of CD36 at the sarcolemma may
also cause cardiac dysfunction [59]. For example,
recent work has shown that during the development of
insulin resistance, CD36 becomes permanently local-
ized at the sarcolemma at the cost of intracellular stor-
age [60]. The resulting increase in fatty acid entry into
cardiomyocytes has been suggested to be an important
contributor to increased intracellular stores of triacyl-
glycerol observed in hearts from diabetics and in ani-
mal models of type 2 diabetes [60]. Moreover, this
increased storage may contribute to diabetic cardiomy-
opathy [60]. Thus, normal cardiac function is depen-
dent on the proper amount and intracellular
localization of CD36 while deviations from its optimal
localization and expression likely play a role in many
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cardiovascular diseases that involve abnormal fatty
acid utilization.
Cellular CD36 content is regulated at different
levels, including gene expression, mRNA stability, and
protein expression in a cell- and tissue-specific manner
[71]. Different physiological conditions, where the
nutritional and/or hormonal status of the individual is
affected, have been shown to impact on CD36 levels
present in the plasma membrane. Regulation at the
level of mRNA expression in skeletal muscle has been
reported to include starvation, refeeding, and exercise
[72], but only few studies have reported the molecular
mechanisms underlying these effects. A previous study
has reported that CD36 expression was activated dur-
ing 3T3-L1 adipocyte differentiation, and CD36 pro-
tein levels were positively correlated with CCAAT/
enhancer-binding protein a (C/EBPa) and PPARc
[73]. Overexpression of C/EBPa or C/EBPb increased
CD36 mRNA and protein levels in several types of
cells. Restoration of C/EBPa or C/EBPb expression in
C/EBPa- or C/EBPb-deficient mouse embryonic
fibroblasts increased CD36 expression. A C/EBP-
responsive element was identified in the CD36 pro-
moter using 50 and specific site mutations, thereby
identifying as a C/EBPa as a transcriptional regulator
of CD36 gene expression [73]. In another study,
sequence analysis of the human CD36 promoter region
revealed a functional hypoxia-inducible factor (HIF)-
1-, the major hypoxia effector, binding site [74]. These
responses were reliant upon ROS production. Interest-
ingly, this study also demonstrated that inhibition of
the PI3K pathway blocked the HIF-1-dependent
induction of CD36 expression and promoter activity,
thus indicating a novel mechanism interlinking hypox-
ia, ROS, and PI3K signaling pathways in the context
of CD36 gene regulation [74]. Additionally, although
PPARa, PPARc [75,76], NR4A (Nur77) [77], Nrf2
[78], and Meox2/Tcf15 heterodimer [79] have been
shown each to affect CD36 expression, no direct bind-
ing of these transcription factors to the Cd36 promoter
have been described. Furthermore, recent analyses of
the Cd36 gene have revealed a complicated promoter
structure with alternative transcription start sites [80].
Alternative promoter usage has been shown to con-
tribute to tissue-specific regulation of CD36 expression
in both mice and humans [80]. Although the alterna-
tive promoters are mapped in the human and murine
Cd36 genes, less information is available for the rat
gene. This intricate fine tuning of Cd36 gene regulation
would be consistent with the concept that the meta-
bolic effects of CD36 involve its ability to function
under the control of different molecular complexes of
several functional proteins.
Future perspectives
As encountered with every biological process, the regu-
lations of GLUT4 and CD36 gene expression and
translocation are complex processes and have impor-
tant further implications for modulation of glucose
and fatty acid metabolism, calcium homeostasis, and
cellular inflammation. Our tools of using non- and/or
supraphysiological in vitro systems and gross genetic
modifications of animal models may fail to identify all
the critical contributors involved in physiological pro-
cesses that are often redundant or, in most cases, are
highly context dependent. Recent insights have shed
light into the roles of GLUT4 and CD36 in the heart
both under homeostatic and patho-physiological con-
ditions but many questions remain unanswered.
The role of GLUT4 as a dominant regulator of
whole-body glucose homeostasis is now well estab-
lished based on several genetically engineered mouse
models overexpressing or deficient of GLUT4. These
data validate the notion that either acute or long-term
changes in the abundance of GLUT4 on the cell sur-
face of heart, adipose, or muscle cells could provoke
systemic changes in glucose disposal in vivo. Such
changes include decreased GLUT4 expression in adi-
pocytes in obesity and increased GLUT4 expression in
cardiac and muscle cells in response to contraction.
However, we are still at an early stage of understand-
ing the regulatory molecular mechanisms that underlie
GLUT4 expression in these tissues. Few transcription
factors involved in GLUT4 gene regulation have been
identified, but their exact roles within the various
physiological conditions that alter GLUT4 expression
need to be further clarified. Other transcriptional regu-
lators also likely play important roles and remain to
be discovered.
On the other hand, what role does CD36 play in
myocardial fatty acid uptake and how is its function
altered in disease? What are the post-translational
modifications responsible for the regulation of CD36
metabolic actions as well as dysfunctional CD36 per-
sistence at the sarcolemma under conditions of hyper-
insulinemia? Is it possible to prevent or reverse these
modifications, and thus ameliorate lipid abnormalities
associated with metabolic syndromes and cardiovascu-
lar diseases? Would enhancing CD36 expression in the
myocardium be beneficial in helping resolve cardiac
injury and how will this impact on metabolic repro-
gramming? In addition to these questions there are
several emerging research avenues that need to be
addressed. Identifying the molecular partners and
interactions that define these regulatory effects would
provide great insight into potential therapeutic targets.
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It is also highly likely that the ability of CD36 to regu-
late cellular metabolism is not limited to lipid uptake
and utilization. The generation of transgenic animals
with inducible and tissue-specific overexpression or
deletion of substrate transporters (GLUT4, CD36) is
currently underway and will provide specific insight
into the role of the substrate transporters in selected
tissues as well as their role in the cross-talk among tis-
sues and in whole body homeostasis.
Finally, much progress is needed in translating these
research approaches to humans, where common vari-
ants in the Cd36 gene impact its expression level often
in a tissue-specific manner [81]. The human genome is
complex owing to multiple promoters and transcripts
with tissue- or cell-specific distribution [80] and under-
standing how these transcripts are regulated is likely to
have relevance to myocardial metabolism. The emerg-
ing availability of noninvasive imaging techniques,
such as magnetic resonance imaging (MRI) and posi-
tron emission tomography (PET), will allow detailed
functional (MRI) and metabolic [e.g., cardiac
18F-fluoro-2-deoxyglucose (FDG) and 18F-fluoro-6-
thioheptadecanoic acid (FTHA) PET imaging]
characterization of individuals. Subsequently, putative
associations between variants in the Glut4 and/or Cd36
genes with these phenotypic characteristics then can be
explored. Furthermore, potential epigenetic influences
of nutrients and of other environmental factors on
GLUT4 and CD36 transcription also might provide
insight into the etiology of metabolic dysfunction and
the associated cardiovascular complications.
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